TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kuros Biosciences ( (CH:KURN) ) has shared an update.
Kuros Biosciences is addressing media inquiries regarding the resignation of former Board member Albert Arp, who allegedly shared price-sensitive information with an unrelated third party. The company is conducting an internal investigation but assures that this issue does not affect its strategic direction, financial results, or operations.
The most recent analyst rating on (CH:KURN) stock is a Buy with a CHF32.50 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a company focused on discovering, developing, and delivering innovative biologic technologies. With operations in the United States, Switzerland, and the Netherlands, it is listed on the SIX Swiss Exchange. The company’s flagship product, MagnetOs, is an advanced bone graft used globally, known for its unique technology that stimulates bone growth without added cells or growth factors.
Average Trading Volume: 239,328
Technical Sentiment Signal: Buy
Current Market Cap: CHF867.1M
Learn more about KURN stock on TipRanks’ Stock Analysis page.